Loading...
01/11 04:03
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call shows strong financial performance with growth in sales and improved margins. The company's strategic partnerships, especially with J&J, are poised to boost future growth. The market opportunity for EXPAREL and positive feedback on the pipeline reinforce optimism. Share repurchases signal confidence in undervaluation. Despite some unclear management responses, overall guidance and strategic initiatives support a positive sentiment.
EXPAREL sales $139.9 million in Q3 2025, up from $132.0 million in Q3 2024, representing a 6% increase. The growth was driven by a 9% increase in volume, partially offset by a shift in vial mix and discounting from the third GPO going live.
Zilretta sales $29.0 million in Q3 2025, up from $28.4 million in Q3 2024, showing a slight increase. The growth is attributed to new partnerships and commercial investments.
iovera sales $6.5 million in Q3 2025, up from $5.7 million in Q3 2024, reflecting a growth driven by a dedicated sales force and commercial investments.
Non-GAAP gross margin 82% in Q3 2025, up from 78% in Q3 2024. The improvement is due to enhanced manufacturing efficiencies and the elimination of the EXPAREL royalty obligation.
Non-GAAP R&D expense $22.5 million in Q3 2025, up from $17.3 million in Q3 2024. The increase is due to strong enrollment in the Phase II study for PCRX-201 and expenses related to Zilretta and iovera registrational studies.
Non-GAAP SG&A expense $81.7 million in Q3 2025, up from $65 million in Q3 2024. The rise is attributed to investments in commercial, medical, and market access organizations, as well as targeted marketing initiatives and field force expansion.
Adjusted EBITDA $49.4 million in Q3 2025, reflecting significant operating cash flow and disciplined capital allocation.
Cash and investments Approximately $246 million at the end of Q3 2025, indicating a strong financial position.
EXPAREL: Year-over-year volumes increased by approximately 9%, marking the highest quarterly growth in over 3 years. Expanded market access and utilization are driving growth.
AMT-143: In-licensed as a complementary long-acting non-opioid pain relief product. Demonstrated sustained analgesic release through 14 days in Phase I study. Phase II program to begin next year.
PCRX-201: Advancing in a Phase II study for osteoarthritis of the knee. Enrollment for Part A concluded ahead of plan. Demonstrated sustained efficacy in Phase I study with improvements in pain, stiffness, and function for over 3 years.
EXPAREL Market Access: Expanded reimbursement coverage to nearly 90 million lives across commercial and government payers. Strong adoption in ambulatory surgery centers with volumes up more than 25% year-over-year.
Zilretta: New initiatives and partnership with J&J MedTech to expand reach. Performance-based agreements and patient support programs introduced.
Manufacturing Efficiencies: Improved manufacturing efficiencies contributed to increased gross margins, now at 82% compared to 78% last year.
Financial Strength: Ended the quarter with $246 million in cash and investments. Executed $50 million in share repurchases.
5x30 Strategy: Focused on growing commercial business and advancing innovative pipeline. Includes in-licensing of AMT-143 and development of PCRX-201.
Intellectual Property: Strengthened EXPAREL patent estate with the listing of the 21st patent in the FDA's Orange Book.
Regulatory and Legal Risks: The company faces Paragraph IV notifications, indicating potential generic competition for its flagship product, EXPAREL. While the company has strengthened its patent estate, generic attempts are common for successful products, and any ANDA filer could pose a threat to the exclusivity and revenue of EXPAREL.
Market Access and Pricing Challenges: Discounting from the third GPO partnership and shifts in vial mix have impacted net selling prices for EXPAREL. Additionally, while the company has expanded coverage for EXPAREL, pricing strategies and reimbursement mechanisms could face challenges in maintaining profitability.
Product-Specific Risks: Zilretta's acceleration has been slower than anticipated, which could impact overall revenue growth. Additionally, the company is investing heavily in new products like AMT-143 and PCRX-201, which are still in early stages of development and carry inherent risks of clinical and commercial success.
Economic and Operational Risks: The company is heavily investing in commercial, medical, and market access organizations, as well as targeted marketing initiatives and field force expansion. These increased SG&A expenses could strain financials if revenue growth does not meet expectations.
Supply Chain and Manufacturing Risks: While the company has improved manufacturing efficiencies, any disruption in the supply chain or manufacturing processes could adversely impact gross margins and product availability.
Revenue Guidance: The company has increased its full-year revenue guidance to a range of $725 million to $735 million for 2025, driven by strong performance in EXPAREL and iovera, although Zilretta's growth has been slower than expected.
Gross Margin Guidance: The full-year non-GAAP gross margin guidance has been raised to 80%-82%, up from the previous range of 78%-80%, due to improved manufacturing efficiencies, favorable production volumes, and the elimination of the EXPAREL royalty obligation.
EXPAREL Growth Expectations: EXPAREL is expected to be a key growth driver, with volume growth projected to continue due to expanded market access, improved reimbursement policies, and increased utilization in ambulatory surgery centers and hospitals.
Pipeline Development: The company plans to initiate a Phase II program for AMT-143, a novel long-acting formulation of bupivacaine, in 2026, with commercialization expected within the 5x30 time frame. PCRX-201 is advancing in a Phase II study for osteoarthritis of the knee, with 12-month data expected next year.
Zilretta and iovera Outlook: Zilretta's growth is expected to improve with new partnerships and commercial investments, while iovera is projected to see continued growth due to a dedicated sales force and improved reimbursement policies.
Capital Allocation: The company plans to continue disciplined capital allocation, focusing on accelerating growth, advancing the pipeline, and opportunistic share repurchases, with $200 million remaining under the current buyback authorization through 2026.
Share Repurchase: During the third quarter, we executed an additional $50 million in share repurchases and retired approximately 2 million shares of common stock. To remind you, we have approximately $200 million remaining under our current share buyback authorization, which runs through the end of 2026. We will continue to be opportunistic with stock repurchases given what we believe is a significant disconnect in our market valuation.
The earnings call shows strong financial performance with growth in sales and improved margins. The company's strategic partnerships, especially with J&J, are poised to boost future growth. The market opportunity for EXPAREL and positive feedback on the pipeline reinforce optimism. Share repurchases signal confidence in undervaluation. Despite some unclear management responses, overall guidance and strategic initiatives support a positive sentiment.
The earnings report shows strong financial performance, with record high gross margins and a new partnership with J&J MedTech, enhancing growth prospects. Despite some declines in specific product sales, the overall outlook remains optimistic with raised guidance and shareholder-friendly actions like stock repurchase. The Q&A revealed some management evasiveness, but the positive aspects outweigh these concerns, suggesting a positive stock price movement.
The earnings call indicates strong financial performance with increased EXPAREL sales and improved gross margins. The stock repurchase program signals confidence in future growth, while guidance aligns with strategic goals. Despite concerns in the Q&A about adoption and competition, the optimistic guidance and strategic initiatives suggest a positive outlook. The positive impact of financial metrics and shareholder returns outweighs the uncertainties, leading to a predicted stock price increase of 2% to 8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
